131 related articles for article (PubMed ID: 20376002)
1. Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.
Hoever P; de Haas S; Winkler J; Schoemaker RC; Chiossi E; van Gerven J; Dingemanse J
Clin Pharmacol Ther; 2010 May; 87(5):593-600. PubMed ID: 20376002
[TBL] [Abstract][Full Text] [Related]
2. Tolerability, pharmacokinetics, and pharmacodynamics of single-dose almorexant, an orexin receptor antagonist, in healthy elderly subjects.
Hoever P; Hay J; Rad M; Cavallaro M; van Gerven JM; Dingemanse J
J Clin Psychopharmacol; 2013 Jun; 33(3):363-70. PubMed ID: 23609389
[TBL] [Abstract][Full Text] [Related]
3. Orexin receptor antagonism: an ascending multiple-dose study with almorexant.
Hoever P; de Haas SL; Dorffner G; Chiossi E; van Gerven JM; Dingemanse J
J Psychopharmacol; 2012 Aug; 26(8):1071-80. PubMed ID: 22695489
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.
Steiner MA; Lecourt H; Strasser DS; Brisbare-Roch C; Jenck F
Neuropsychopharmacology; 2011 Mar; 36(4):848-56. PubMed ID: 21150905
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
[TBL] [Abstract][Full Text] [Related]
6. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
Neubauer DN
Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
[TBL] [Abstract][Full Text] [Related]
7. Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant.
Hoch M; van Gorsel H; van Gerven J; Dingemanse J
J Clin Pharmacol; 2014 Sep; 54(9):979-86. PubMed ID: 24691844
[TBL] [Abstract][Full Text] [Related]
8. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.
Mang GM; Dürst T; Bürki H; Imobersteg S; Abramowski D; Schuepbach E; Hoyer D; Fendt M; Gee CE
Sleep; 2012 Dec; 35(12):1625-35. PubMed ID: 23204605
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
Cruz HG; Hay JL; Hoever P; Alessi F; te Beek ET; van Gerven JM; Dingemanse J
Eur Neuropsychopharmacol; 2014 Aug; 24(8):1257-68. PubMed ID: 24880753
[TBL] [Abstract][Full Text] [Related]
10. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.
Dugovic C; Shelton JE; Aluisio LE; Fraser IC; Jiang X; Sutton SW; Bonaventure P; Yun S; Li X; Lord B; Dvorak CA; Carruthers NI; Lovenberg TW
J Pharmacol Exp Ther; 2009 Jul; 330(1):142-51. PubMed ID: 19363060
[TBL] [Abstract][Full Text] [Related]
11. Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects.
Hoch M; Hoever P; Zisowsky J; Priestley A; Fleet D; Dingemanse J
Pharmacology; 2012; 89(1-2):53-7. PubMed ID: 22302127
[TBL] [Abstract][Full Text] [Related]
12. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
Malherbe P; Borroni E; Pinard E; Wettstein JG; Knoflach F
Mol Pharmacol; 2009 Sep; 76(3):618-31. PubMed ID: 19542319
[TBL] [Abstract][Full Text] [Related]
13. Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist.
Bettica P; Nucci G; Pyke C; Squassante L; Zamuner S; Ratti E; Gomeni R; Alexander R
J Psychopharmacol; 2012 Aug; 26(8):1058-70. PubMed ID: 21730017
[TBL] [Abstract][Full Text] [Related]
14. Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans.
Dingemanse J; Hoever P; Hoch M; Treiber A; Wagner-Redeker W; Miraval T; Hopfgartner G; Shakeri-Nejad K
Drug Metab Dispos; 2013 May; 41(5):1046-59. PubMed ID: 23431113
[TBL] [Abstract][Full Text] [Related]
15. Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects.
Hoch M; Hoever P; Haschke M; Krähenbühl S; Dingemanse J
J Clin Pharmacol; 2011 Jul; 51(7):1116-21. PubMed ID: 20852003
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics and tolerability of almorexant in Japanese and Caucasian healthy male subjects.
Hoch M; Hoever P; Alessi F; Marjason J; Dingemanse J
Pharmacology; 2011; 88(3-4):121-6. PubMed ID: 21865769
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia.
Bettica P; Squassante L; Groeger JA; Gennery B; Winsky-Sommerer R; Dijk DJ
Neuropsychopharmacology; 2012 Apr; 37(5):1224-33. PubMed ID: 22237311
[TBL] [Abstract][Full Text] [Related]
18. Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial.
Hoever P; Dorffner G; Beneš H; Penzel T; Danker-Hopfe H; Barbanoj MJ; Pillar G; Saletu B; Polo O; Kunz D; Zeitlhofer J; Berg S; Partinen M; Bassetti CL; Högl B; Ebrahim IO; Holsboer-Trachsler E; Bengtsson H; Peker Y; Hemmeter UM; Chiossi E; Hajak G; Dingemanse J
Clin Pharmacol Ther; 2012 Jun; 91(6):975-85. PubMed ID: 22549286
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
[TBL] [Abstract][Full Text] [Related]
20. Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant.
Dietrich H; Jenck F
Psychopharmacology (Berl); 2010 Oct; 212(2):145-54. PubMed ID: 20631993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
